Vico Therapeutics Secures $91M to Accelerate Breakthrough RNA Therapies for Neurological Disorders

Vico Therapeutics is excited to announce a significant milestone in our journey toward transforming the landscape of genetic neurological disorder treatments, as we have successfully raised $91,000,000 in our latest round of funding. This pivotal investment underscores the confidence that investors have in our innovative VICOMER platform, which is at the forefront of designing antisense oligonucleotides aimed at modulating or editing RNA to correct various genetic defects. With a sharp focus on severe, inherited neurological disorders, Vico Therapeutics is initially directing its R&D efforts towards targeting spinocerebellar ataxia types 3 and 1 as well as Huntington’s disease, conditions that have long posed a challenge due to their complex genetic underpinnings and limited treatment options. The newly raised capital will be strategically deployed to accelerate the development of our RNA modulating therapies, enhance clinical trials, and expand our research capabilities. We are committed to harnessing the potential of our cutting-edge therapeutic platform to not only improve patient outcomes but also to pave the way for new treatment paradigms in the field of genetic medicine. By boosting our R&D programs and investing in state-of-the-art technologies, we aim to shorten the timeline from discovery to clinical implementation, ultimately offering hope to countless patients and families affected by these debilitating conditions. This funding round represents both a validation of our scientific approach and a catalyst for future innovation, as we continue to drive forward our mission of pioneering effective, life-changing treatments. For more information on our work and ongoing progress, please visit www.vicotx.com.